Evidence map›Paper›PMID 30107522›Full record

ArticlePathogens and disease2018

Estimating treatment prolongation for persistent infections.

Antal Martinecz, Pia Abel Zur Wiesch

Abstract read
In one paragraph

Article in Pathogens and disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Deciphering meropenem persistence inAntimicrobial agents and chemotherapy · 2025
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Understanding tolerance to cell wall-active antibiotics.Annals of the New York Academy of Sciences · 2021
    Review
  7. Article
  8. Reaction Kinetic Models of Antibiotic Heteroresistance.International journal of molecular sciences · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Antal MartineczDepartment of Pharmacy, Faculty of Health Sciences, UiT The Arctic University of Norway, 9037 Tromsø.
Pia Abel Zur WieschDepartment of Pharmacy, Faculty of Health Sciences, UiT The Arctic University of Norway, 9037 Tromsø.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment of infectious diseases is often long and requires patients to take drugs even after they have seemingly recovered. This is because of a phenomenon called persistence, which allows small fractions of the bacterial population to survive treatment despite being genetically susceptible. The surviving subpopulation is often below detection limit and therefore is empirically inaccessible but can cause treatment failure when treatment is terminated prematurely. Mathematical models could aid in predicting bacterial survival and thereby determine sufficient treatment length. However, the mechanisms of persistence are hotly debated, necessitating the development of multiple mechanistic models. Here we develop a generalized mathematical framework that can accommodate various persistence mechanisms from measurable heterogeneities in pathogen populations. It allows the estimation of the relative increase in treatment length necessary to eradicate persisters compared to the majority population. To simplify and generalize, we separate the model into two parts: the distribution of the molecular mechanism of persistence in the bacterial population (e.g. number of efflux pumps or target molecules, growth rates) and the elimination rate of single bacteria as a function of that phenotype. Thereby, we obtain an estimate of the required treatment length for each phenotypic subpopulation depending on its size and susceptibility.

Indexed as

TimeAnti-Bacterial AgentsBacterial InfectionsDrug TherapyHumansMicrobial ViabilityModels, TheoreticalAnti-Bacterial Agents

Identifiers

PMID30107522
PMCPMC6134427

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.